Levels of cytokine in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation

Journal of Interferon and Cytokine Research

Volumn 27, Issue 1, 2007, Pages 38-43

  Emad, Ali ^a   Emad, Yasaman ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MUSTARD GAS; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; TRANSBRONCHIAL BIOPSY; VETERAN;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; HUMANS; MALE; MIDDLE AGED; MUSTARD GAS; PULMONARY FIBROSIS;

EID: 33846568939     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.0084     Document Type: Article

References (28)

1. Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol. Rev. 1996;48:289-326.
2. Smith KJ, Skelton H. Chemical warfare agents. Their past and continuing threat and evolving therapies. Part I. Skin Med. 2003;2:215-221.
3. Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997;112:734-738.
4. Urbannetti JS. Battlefield chemical inhalation injury. In: Luke J, ed. Pathophysiology and Treatment of Inhalation Injuries. New York: Dekker, 1988;34:281-348.
5. Emad A, Rezaian GR. Characteristics of bronchoalveolar lavage fluid in patients with sulfur mustard gas-induced asthma or chronic bronchitis. Am. J. Med. 1999;106:689-690.
6. Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Chest 1999;115:1346-1351.
7. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med. 2000;161:646-664.
8. Gardner R, Kankinson J, Clausen J. Standardization of spirometry-1987 update. Am. Rev. Respir. Dis. 1987;136:1285-1298.
9. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault J-C. Standardization of the measurement of transfer factor (diffusing capacity). Report of the working party, Standardization of lung function tests, European Community for steel and coal. Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 1993;16:41-52.
10. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am. Rev. Respir. Dis. 1991;144:1202-1218.
11. Calvet JH, Jarreau PH, Levame M, D'Ortho MP, Lorino H, Harf A, Macquin-Mavier I. Acute and chronic respiratory effects of sulfur mustard intoxication in guinea pig. J. Appl. Physiol. 1994; 76:681-688.
12. Chevillard M, Lainee P, Robineau P. Toxic effects of sulfur mustard on respiratory epithelial cells in culture. Cell. Biol. Toxicol. 1992;8:171-181.
13. Dompeling E, Jöbsis Q, Vandevijver NM. A, Wesseling G, Hendriks H. Chronic bronchiolitis in a 5-yr-old child after exposure to sulphur mustard gas. Eur. Resp. J. 2004;23:343-346.
14. Strieter RM, Chensue SW, Basha MA. Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-alpha, lipopolysaccharide, and interleukin-1beta. Am. J. Respir. Cell. Mol. Biol. 1990;2:321-326.
15. Losa Garcia JE, Rodriguez FM, Martin de Cabo MK, Garcia Salgado MJ, Losada JP, Villaron LG, Lopez AJ, Arellano JL. Evaluation of inflammatory cytokine secretion by human alveolar macrophages. Mediators Inflamm. 1999;8:143-151.
16. Schultz C, Wolf K, Harth M. Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration 2003;70:254-261.
17. Southcott A, Jones A, Majumdar S, Cambrey A, Pantelidis C, Black C, Laurent G, Davies B, Jeffery P, duBois R. Interleukin-8: differential expression in lone fibrosing alveolitis and systemic sclerosis. Am. J. Respir. Crit. Care Med. 1995;151:1604-1612.
18. Folkard SG, Westwick J, Millar AB. Production of interleukin-8, RANTES and MCP-1 in intrinsic and extrinsic asthmatics. Eur. Respir. J. 1997;10:2097-2104.
19. Keatings VM, Collins PD, Scott DM. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996;153:530-534.
20. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 1998;16:495-521.
21. Randow F, Do È Cke WD, Bundschuh DS, Hartung T, Wendel A, Volk HD. In vitro prevention and reversal of lipopolysaccharide desensitization by IFN-γ, IL-12, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 1997;158:2911-2918.
22. D'Andrea A, Aste-amezaga M, Valiante NM, MA X, Kubin M, Trinchieri G. Interleukin 10 inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993; 178:1041-1048.
23. Blobe GC, Schiemann WP, Lodish HF. Mechanisms of disease: role of transforming growth factor-β in human disease. N. Engl. J. Med. 2000;342:1350-1358.
24. Border WA, Nobel NA. Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 1994;331:1286-1291.
25. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 1991;88:6642-6646.
26. Coker RK, Laurent GJ, Jeffery PK, du Bois RM, Black CM, McAnulty RJ. Localisation of transforming growth factor β1 and β2 mRNA transcripts in normal and fibrotic human lung. Thorax 2001;56:549-556.
27. Tarnawski A. Molecular mechanisms of ulcer healing. Drug News Perspect. 2000;13:158-168.
28. Ziesche R, Hofbauer E, Witmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1betha and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999;341:1264-1269.